Rivastigmine for Dementia Associated with Parkinson's Disease | Zendy

Murat Emre | Zendy; Dag Aarsland | Zendy; Alberto Albanese | Zendy; E. Jane Byrne | Zendy; Günther Deuschl | Zendy; Peter Paul De Deyn | Zendy; Franck Durif | Zendy; Jaime Kulisevsky | Zendy; Teus van Laar | Zendy; Andrew Lees | Zendy; Werner Poewe | Zendy; Alain Robillard | Zendy; Màrio Miguel Rosa | Zendy; Erik Ch. Wolters | Zendy; Peter Quarg | Zendy; Sibel Tekin | Zendy; Roger Lane | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivastigmine for Dementia Associated with Parkinson's Disease

Author(s) -

Murat Emre,

Dag Aarsland,

Alberto Albanese,

E. Jane Byrne,

Günther Deuschl,

Peter Paul De Deyn,

Franck Durif,

Jaime Kulisevsky,

Teus van Laar,

Andrew Lees,

Werner Poewe,

Alain Robillard,

Màrio Miguel Rosa,

Erik Ch. Wolters,

Peter Quarg,

Sibel Tekin,

Roger Lane

Publication year - 2004

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa041470

Subject(s) - rivastigmine , medicine , dementia , placebo , donepezil , clinical global impression , clinical trial , alzheimer's disease , disease , physical therapy , psychiatry , pathology , alternative medicine

Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research